Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Metronidazole DR Capsules vs IR Tablets in Healthy Subjects
NCT07251127Phase 1Completed
- Sponsor
- Gateway Pharmaceutical
- Start
- May 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of metronidazole in Clostridioides difficile infection (CDI) (2 arms), sponsored by Gateway Pharmaceutical. Primary endpoints: Area under the curve up to 3 days and Maximum Plasma Concentration up to 3 days. Started May 2025; status: completed.
02
Drugs
metronidazole
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT07251127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07251127.